Tech Center 1600 • Art Units: 1633 1638 1653
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17922633 | CAS9-BASED DIAGNOSTIC ASSAY AND METHODS OF USING | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18251314 | ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY CELL-BASED POTENCY ASSAY | Non-Final OA | MERCK SHARP & DOHME LLC |
| 17997429 | MODEL-BASED CONTROL FOR COLUMN-BASED CONTINUOUS VIRAL INACTIVATION OF BIOPHARMACEUTICALS | Non-Final OA | Massachusetts Institute of Technology |
| 17995671 | INTEGRATION OF LARGE ADENOVIRUS PAYLOADS | Final Rejection | University of Washington |
| 18465547 | HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18506193 | SYNTHETIC NUCLEIC ACIDS INCLUDING ASTROCYTE-DIRECTED PROMOTER CONSTRUCTS AND METHODS OF USING THE SAME | Non-Final OA | Eli Lilly and Company |
| 18288817 | Compositions Comprising Adeno-Associated Virus Chimera Capsid Proteins and Methods of Using the Same | Non-Final OA | Duke University |
| 17920152 | Hematological Parameter for Viral Infection | Non-Final OA | Beckman Coulter, Inc. |
| 17768002 | GENETICALLY MODIFIED HUMAN STEM CELL EXPRESSING A MUTANT HUMAN CYTOCHROME P450 2B6 PROTEIN AND ITS USE THEREOF IN THE TREATMENT OF CANCER | Non-Final OA | SORBONNE UNIVERSITE |
| 17827338 | INDUCTION OF ARTERIAL-TYPE OF HEMOGENIC ENDOTHELIUM (AHE) AND ENHANCEMENT OF T CELL PRODUCTION FROM PSCS THROUGH OVEREXPRESSION OF ETS FACTORS OR MODULATING MAPK/ERK SIGNALLING PATHWAYS | Final Rejection | Wisconsin Alumni Research Foundation |
| 17263433 | COMPOSITION FOR SUPPRESSION OF AGING, PREVENTION, AMELIORATION, OR TREATMENT OF AN AGE-RELATED DISEASE OR SYMPTOM, OR EXTENSION OF LIFESPAN | Final Rejection | OSAKA UNIVERSITY |
| 18069621 | CIRCULAR RNA COMPOSITIONS AND METHODS | Final Rejection | Orna Therapeutics, Inc. |
| 17929574 | COMPOSITIONS AND METHODS FOR ANALYTE DETECTION | Non-Final OA | Colorado State University Research Foundation |
| 18029112 | Use of an intervertebral disc fibrosis-inducing substance in preparation of medication | Non-Final OA | Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine |
| 18118072 | METHODS AND COMPOSITIONS FOR DETECTING RISK OF CANCER RELAPSE | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17292923 | METHODS FOR INDUCING IMMUNE TOLERANCE | Non-Final OA | Translate Bio, Inc. |
| 18147365 | RNA ENCODING AN ANTIBODY | Non-Final OA | CureVac SE |
| 18286835 | SIGNAL SEQUENCE THAT INDUCES PROTEIN SECRETION IN INTESTINAL MICROBIOME | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 17610637 | AGENT THAT ENABLES SIRT7 GENE EXPRESSION AND THE USE THEREOF | Final Rejection | SHENZHEN UNIVERSITY |
| 18537897 | BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER | Non-Final OA | Synlogic Operating Company, Inc. |
| 18326637 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | Non-Final OA | Synlogic Operating Company, Inc. |
| 18564318 | SCAFFOLD FOR CELL CULTURE | Non-Final OA | SEA WITH, INC |
| 18515458 | CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | AUTOLUS LIMITED |
| 18321517 | Cell | Non-Final OA | AUTOLUS LIMITED |
| 18282061 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRHYTHMOGENIC CARDIOMYOPATHY | Final Rejection | UCL BUSINESS LTD |
| 18558226 | METHOD FOR PRODUCING VASCULARIZED BIOLOGICAL TISSUE | Non-Final OA | Universitaet des Saarlandes |
| 17921291 | STABILIZATION OF POLYETHYLENEIMINE-DEOXYRIBONUCLEIC ACID COMPLEX SIZE AND ACTIVITY | Non-Final OA | Juno Therapeutics, Inc. |
| 18285560 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS | Non-Final OA | Spirovant Sciences, Inc. |
| 17439921 | EXPRESSION CONSTRUCTS FOR THE GENETIC MODIFICATION OF CELLS | Final Rejection | Deutsches Krebsforschungszentrum |
| 18238074 | POLYMERIC MICELLE COMPOSITIONS | Non-Final OA | UVic Industry Partnerships Inc.- Univ. of Victoria |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy